Fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy

Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy Why was the study done? Complaints of fatigue and poor sleep quality are common in patients with epilepsy. A crucial problem related to fatigue is that it...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic advances in neurological disorders Vol. 18; p. 17562864251325338
Main Authors Zhong, Rui, Zhao, Teng, Li, Nan, Li, Jing, Li, Guangjian, Zhang, Xinyue, Lin, Weihong
Format Journal Article
LanguageEnglish
Published England SAGE Publications 01.01.2025
SAGE Publishing
Subjects
Online AccessGet full text
ISSN1756-2864
1756-2856
1756-2864
DOI10.1177/17562864251325338

Cover

Loading…
Abstract Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy Why was the study done? Complaints of fatigue and poor sleep quality are common in patients with epilepsy. A crucial problem related to fatigue is that it may precipitate a single or multiple seizures. Patients with poor sleep quality also have high seizures frequency and depression symptoms. We wondered whether patients with fatigue or poor sleep quality have higher risk of developing resistance to anti-seizure medication. We also investigate the role of depression symptoms in the relationship. What did the researchers do? The research team invited patients with newly diagnosed epilepsy to participate in this study in Northeast China. The participants were asked to complete questionnaires to assess fatigue, sleep quality and depression symptoms. Then the participants were treated with anti-seizure medications. The researchers observed how the patients responded to the anti-seizure medications over 24-month period. What did the researchers find? A total of 189 patients participated in this study. We observed that 59 patients had resistance to anti-seizure medication and 130 responded well to drugs. Patients who had fatigue were more likely to experience drug resistance. Similarly, patients who had poor sleep quality were more likely to have drug resistance. Additionally, depression symptoms play an important in the effect of fatigue and sleep quality on drug responsiveness. What do the findings mean? This study has some important findings. Patients who had fatigue or poor sleep quality were more likely to responded poorly to anti-seizure medications. We also observed the mediating role of depression severity. These findings tell us the importance of assessing fatigue, sleep quality and depression symptoms in patients with newly diagnosed epilepsy which may help identify those at greater risk of drug resistance.
AbstractList Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy Why was the study done? Complaints of fatigue and poor sleep quality are common in patients with epilepsy. A crucial problem related to fatigue is that it may precipitate a single or multiple seizures. Patients with poor sleep quality also have high seizures frequency and depression symptoms. We wondered whether patients with fatigue or poor sleep quality have higher risk of developing resistance to anti-seizure medication. We also investigate the role of depression symptoms in the relationship. What did the researchers do? The research team invited patients with newly diagnosed epilepsy to participate in this study in Northeast China. The participants were asked to complete questionnaires to assess fatigue, sleep quality and depression symptoms. Then the participants were treated with anti-seizure medications. The researchers observed how the patients responded to the anti-seizure medications over 24-month period. What did the researchers find? A total of 189 patients participated in this study. We observed that 59 patients had resistance to anti-seizure medication and 130 responded well to drugs. Patients who had fatigue were more likely to experience drug resistance. Similarly, patients who had poor sleep quality were more likely to have drug resistance. Additionally, depression symptoms play an important in the effect of fatigue and sleep quality on drug responsiveness. What do the findings mean? This study has some important findings. Patients who had fatigue or poor sleep quality were more likely to responded poorly to anti-seizure medications. We also observed the mediating role of depression severity. These findings tell us the importance of assessing fatigue, sleep quality and depression symptoms in patients with newly diagnosed epilepsy which may help identify those at greater risk of drug resistance.
Background: Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have higher frequency of seizures and are more likely to have symptoms of depression. Objectives: This study aims to determine the association of baseline fatigue and sleep quality with antiseizure medication (ASM) resistance in patients with newly diagnosed epilepsy (PWNDE). We also evaluate whether the association is mediated by depression symptoms. Methods: We performed a prospective cohort study of PWNDE at comprehensive epilepsy center in Northeast China between June 2020 and May 2024. Fatigue, sleep quality, and depression symptoms were assessed at baseline. All patients were followed for 24 months for ASM-resistant epilepsy. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) of ASM resistance. Models fitted with restricted cubic spline were performed to test for linear and nonlinear shapes of each association. Mediation analysis was used to estimate the mediating effects of depression severity on association between fatigue, sleep quality, and ASM resistance. Results: A total of 189 patients (59 ASM-resistant cases and 130 ASM-responsive controls) were included in the final analysis. Baseline fatigue (HR, 1.98; 95% confidence interval (CI), 1.094–3.583, p  = 0.024) and poor sleep quality (HR, 2.193; 95% CI, 1.29–3.729, p  = 0.004) were associated with an increased hazard of ASM resistance in PWNDE after full adjustments. There exists a nonlinear association between Fatigue Severity Scale score and the hazard of ASM resistance ( P for nonlinear = 0.012). Depression severity partly mediated the effect of fatigue and sleep quality on ASM resistance, with mediated proportions of 18.5% for the fatigue and 23.7% for the sleep quality. Conclusion: Baseline fatigue and poor sleep quality were associated with an increased risk of ASM resistance. The association between fatigue, sleep quality, and ASM resistance were partly mediated by depression severity. These findings emphasize that patients with ASM-resistant epilepsy are more likely to have fatigue, depression, and poor sleep quality at baseline and this may be unrelated to ASM intake.
Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have higher frequency of seizures and are more likely to have symptoms of depression. This study aims to determine the association of baseline fatigue and sleep quality with antiseizure medication (ASM) resistance in patients with newly diagnosed epilepsy (PWNDE). We also evaluate whether the association is mediated by depression symptoms. We performed a prospective cohort study of PWNDE at comprehensive epilepsy center in Northeast China between June 2020 and May 2024. Fatigue, sleep quality, and depression symptoms were assessed at baseline. All patients were followed for 24 months for ASM-resistant epilepsy. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) of ASM resistance. Models fitted with restricted cubic spline were performed to test for linear and nonlinear shapes of each association. Mediation analysis was used to estimate the mediating effects of depression severity on association between fatigue, sleep quality, and ASM resistance. A total of 189 patients (59 ASM-resistant cases and 130 ASM-responsive controls) were included in the final analysis. Baseline fatigue (HR, 1.98; 95% confidence interval (CI), 1.094-3.583,  = 0.024) and poor sleep quality (HR, 2.193; 95% CI, 1.29-3.729,  = 0.004) were associated with an increased hazard of ASM resistance in PWNDE after full adjustments. There exists a nonlinear association between Fatigue Severity Scale score and the hazard of ASM resistance ( for nonlinear = 0.012). Depression severity partly mediated the effect of fatigue and sleep quality on ASM resistance, with mediated proportions of 18.5% for the fatigue and 23.7% for the sleep quality. Baseline fatigue and poor sleep quality were associated with an increased risk of ASM resistance. The association between fatigue, sleep quality, and ASM resistance were partly mediated by depression severity. These findings emphasize that patients with ASM-resistant epilepsy are more likely to have fatigue, depression, and poor sleep quality at baseline and this may be unrelated to ASM intake.
Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy Why was the study done? Complaints of fatigue and poor sleep quality are common in patients with epilepsy. A crucial problem related to fatigue is that it may precipitate a single or multiple seizures. Patients with poor sleep quality also have high seizures frequency and depression symptoms. We wondered whether patients with fatigue or poor sleep quality have higher risk of developing resistance to anti-seizure medication. We also investigate the role of depression symptoms in the relationship. What did the researchers do? The research team invited patients with newly diagnosed epilepsy to participate in this study in Northeast China. The participants were asked to complete questionnaires to assess fatigue, sleep quality and depression symptoms. Then the participants were treated with anti-seizure medications. The researchers observed how the patients responded to the anti-seizure medications over 24-month period. What did the researchers find? A total of 189 patients participated in this study. We observed that 59 patients had resistance to anti-seizure medication and 130 responded well to drugs. Patients who had fatigue were more likely to experience drug resistance. Similarly, patients who had poor sleep quality were more likely to have drug resistance. Additionally, depression symptoms play an important in the effect of fatigue and sleep quality on drug responsiveness. What do the findings mean? This study has some important findings. Patients who had fatigue or poor sleep quality were more likely to responded poorly to anti-seizure medications. We also observed the mediating role of depression severity. These findings tell us the importance of assessing fatigue, sleep quality and depression symptoms in patients with newly diagnosed epilepsy which may help identify those at greater risk of drug resistance.
Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have higher frequency of seizures and are more likely to have symptoms of depression.BackgroundComplaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have higher frequency of seizures and are more likely to have symptoms of depression.This study aims to determine the association of baseline fatigue and sleep quality with antiseizure medication (ASM) resistance in patients with newly diagnosed epilepsy (PWNDE). We also evaluate whether the association is mediated by depression symptoms.ObjectivesThis study aims to determine the association of baseline fatigue and sleep quality with antiseizure medication (ASM) resistance in patients with newly diagnosed epilepsy (PWNDE). We also evaluate whether the association is mediated by depression symptoms.We performed a prospective cohort study of PWNDE at comprehensive epilepsy center in Northeast China between June 2020 and May 2024. Fatigue, sleep quality, and depression symptoms were assessed at baseline. All patients were followed for 24 months for ASM-resistant epilepsy. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) of ASM resistance. Models fitted with restricted cubic spline were performed to test for linear and nonlinear shapes of each association. Mediation analysis was used to estimate the mediating effects of depression severity on association between fatigue, sleep quality, and ASM resistance.MethodsWe performed a prospective cohort study of PWNDE at comprehensive epilepsy center in Northeast China between June 2020 and May 2024. Fatigue, sleep quality, and depression symptoms were assessed at baseline. All patients were followed for 24 months for ASM-resistant epilepsy. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) of ASM resistance. Models fitted with restricted cubic spline were performed to test for linear and nonlinear shapes of each association. Mediation analysis was used to estimate the mediating effects of depression severity on association between fatigue, sleep quality, and ASM resistance.A total of 189 patients (59 ASM-resistant cases and 130 ASM-responsive controls) were included in the final analysis. Baseline fatigue (HR, 1.98; 95% confidence interval (CI), 1.094-3.583, p = 0.024) and poor sleep quality (HR, 2.193; 95% CI, 1.29-3.729, p = 0.004) were associated with an increased hazard of ASM resistance in PWNDE after full adjustments. There exists a nonlinear association between Fatigue Severity Scale score and the hazard of ASM resistance (P for nonlinear = 0.012). Depression severity partly mediated the effect of fatigue and sleep quality on ASM resistance, with mediated proportions of 18.5% for the fatigue and 23.7% for the sleep quality.ResultsA total of 189 patients (59 ASM-resistant cases and 130 ASM-responsive controls) were included in the final analysis. Baseline fatigue (HR, 1.98; 95% confidence interval (CI), 1.094-3.583, p = 0.024) and poor sleep quality (HR, 2.193; 95% CI, 1.29-3.729, p = 0.004) were associated with an increased hazard of ASM resistance in PWNDE after full adjustments. There exists a nonlinear association between Fatigue Severity Scale score and the hazard of ASM resistance (P for nonlinear = 0.012). Depression severity partly mediated the effect of fatigue and sleep quality on ASM resistance, with mediated proportions of 18.5% for the fatigue and 23.7% for the sleep quality.Baseline fatigue and poor sleep quality were associated with an increased risk of ASM resistance. The association between fatigue, sleep quality, and ASM resistance were partly mediated by depression severity. These findings emphasize that patients with ASM-resistant epilepsy are more likely to have fatigue, depression, and poor sleep quality at baseline and this may be unrelated to ASM intake.ConclusionBaseline fatigue and poor sleep quality were associated with an increased risk of ASM resistance. The association between fatigue, sleep quality, and ASM resistance were partly mediated by depression severity. These findings emphasize that patients with ASM-resistant epilepsy are more likely to have fatigue, depression, and poor sleep quality at baseline and this may be unrelated to ASM intake.
Author Zhong, Rui
Li, Guangjian
Zhang, Xinyue
Lin, Weihong
Li, Nan
Li, Jing
Zhao, Teng
Author_xml – sequence: 1
  givenname: Rui
  surname: Zhong
  fullname: Zhong, Rui
  organization: Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
– sequence: 2
  givenname: Teng
  surname: Zhao
  fullname: Zhao, Teng
  organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China
– sequence: 3
  givenname: Nan
  surname: Li
  fullname: Li, Nan
  organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China
– sequence: 4
  givenname: Jing
  surname: Li
  fullname: Li, Jing
  organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China
– sequence: 5
  givenname: Guangjian
  surname: Li
  fullname: Li, Guangjian
  organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China
– sequence: 6
  givenname: Xinyue
  orcidid: 0000-0002-6434-5599
  surname: Zhang
  fullname: Zhang, Xinyue
  organization: Department of Neurology, The First Hospital of Jilin University, Xinmin Street, No. 1, Changchun, Jilin 130021, China
– sequence: 7
  givenname: Weihong
  orcidid: 0000-0002-5904-5989
  surname: Lin
  fullname: Lin, Weihong
  organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40084242$$D View this record in MEDLINE/PubMed
BookMark eNplkk1rFTEUhoNU7If-ADeSpYt79SSZzMdKpFgtFNzoOmSSM7cpM8k0yVhG_PHm9tbS4iIkvHl4X87HKTnywSMhbxl8YKxpPrJG1rytKy6Z4FKI9gU52WvbvXj05H1MTlO6Aah5U8ErclwBtBWv-An5c6Gz2y24oWlEnOntokeX1w21OEdMyQVP0zrNOUxpQ7W35WSX0P1eItIJrTPFoEAFdilrb5A6T-cios-J3rl8TT3ejSu1Tu98SGgpzm7EOa2vyctBjwnfPNxn5OfFlx_n37ZX379enn--2pqKQ952VS2hES0YqIF3puoBOJhOtkaUygcQAqAxiGh1a3prbD8w3WsBnTGacXFGLg--NugbNUc36biqoJ26F0LcKR2zMyMqed9TZobS1IpJ07VWa13yasPaxnTF69PBa176Ur4pVUY9PjN9_uPdtdqFX4qxDiQIWRzePzjEcLtgympyyeA4ao9hSUqU0TLJC13Qd0_DHlP-za8A7ACYGFKKODwiDNR-R9R_OyL-Ajk7sF4
Cites_doi 10.1111/j.1528-1167.2011.03041.x
10.1016/j.seizure.2013.05.018
10.1016/S0140-6736(18)32596-0
10.1111/epi.17155
10.1016/j.seizure.2016.11.006
10.1093/brain/awab401
10.1016/j.yebeh.2019.106661
10.1007/s11136-005-4346-x
10.1016/S1474-4422(06)70415-X
10.1016/j.yebeh.2022.108688
10.1111/epi.17564
10.1007/s11136-015-1056-x
10.1111/epi.12550
10.1016/j.neubiorev.2016.05.008
10.1016/j.seizure.2020.04.003
10.1111/j.1528-1167.2009.02397.x
10.1016/j.expneurol.2007.09.026
10.1016/0165-1781(89)90047-4
10.1016/j.comppsych.2016.08.004
10.1016/j.tins.2014.06.005
10.1001/archneur.1989.00520460115022
10.1016/S0140-6736(23)01048-6
10.1146/annurev-med-052209-100430
10.1007/s13311-021-01021-w
10.1016/j.yebeh.2014.02.019
10.1016/j.smrv.2021.101466
10.1111/epi.17664
10.1111/epi.17107
10.1016/j.seizure.2015.12.003
10.1016/j.seizure.2022.10.019
10.1016/j.yebeh.2022.108565
10.1016/S1474-4422(23)00151-5
10.1016/j.seizure.2020.10.029
10.1016/j.yebeh.2023.109568
10.1016/j.smrv.2005.03.002
10.1212/WNL.0000000000200959
10.1212/WNL.0000000000209821
10.1016/j.seizure.2022.11.002
10.1111/epi.17454
10.1111/epi.13709
10.1016/j.yebeh.2017.04.030
10.1111/j.1528-1167.2008.01902.x
10.1016/j.sleep.2018.05.010
10.1001/jama.2022.3880
10.1097/WNP.0000000000000806
10.1212/WNL.0b013e3181f25b16
10.1016/j.smrv.2022.101689
10.1111/epi.13651
10.1016/j.yebeh.2015.03.012
10.1111/epi.17710
10.1111/epi.17661
10.1111/epi.13741
10.1038/s41398-022-02297-y
10.1007/s00415-018-8971-z
ContentType Journal Article
Copyright The Author(s), 2025.
The Author(s), 2025 2025 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s), 2025.
– notice: The Author(s), 2025 2025 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1177/17562864251325338
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

PubMed
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Acceso a contenido Full Text - Doaj
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-2864
ExternalDocumentID oai_doaj_org_article_5175621cf425415c98daaa0026c187c9
PMC11905035
40084242
10_1177_17562864251325338
Genre Journal Article
GrantInformation_xml – fundername: ;
  grantid: no.LCPYJJ2017006
– fundername: ;
  grantid: no. YDZJ202201ZYTS040
GroupedDBID ---
-TM
01A
0R~
123
18M
29Q
4.4
53G
54M
5VS
7X7
8FI
8FJ
AABMB
AADUE
AAKDD
AAQDB
AARDL
AARIX
AASGM
AAYXX
ABAWP
ABEIX
ABFWQ
ABJIS
ABKRH
ABNCE
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACHEB
ACOFE
ACROE
ACRPL
ADBBV
ADEBD
ADNMO
ADOGD
ADYCS
ADZZY
AENEX
AEQLS
AERKM
AEUHG
AEWDL
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AFWMB
AGNHF
AGQPQ
AHHFK
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AUTPY
AUVAJ
AVWKF
AYAKG
AZFZN
B8M
BAWUL
BCNDV
BDDNI
BENPR
BKSCU
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
CDWPY
CFDXU
CITATION
COF
CS3
DC-
DC.
DIK
DOPDO
E3Z
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
H13
HMCUK
HVGLF
HYE
HZ~
J8X
K.F
N9A
O9-
OK1
P.B
PHGZM
PHGZT
PIMPY
PQQKQ
PSYQQ
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
M4V
NPM
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c420t-946507380c06029c4b0020c958c3513f033007ceeeda8cbdcdbf1aba309cca123
IEDL.DBID DOA
ISSN 1756-2864
1756-2856
IngestDate Wed Aug 27 01:23:10 EDT 2025
Thu Aug 21 18:34:19 EDT 2025
Thu Sep 04 23:06:38 EDT 2025
Wed Mar 19 01:28:47 EDT 2025
Tue Aug 05 11:59:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords PWNDE
ASM resistance
depression symptoms
fatigue
sleep quality
Language English
License The Author(s), 2025.
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c420t-946507380c06029c4b0020c958c3513f033007ceeeda8cbdcdbf1aba309cca123
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-6434-5599
0000-0002-5904-5989
OpenAccessLink https://doaj.org/article/5175621cf425415c98daaa0026c187c9
PMID 40084242
PQID 3177152905
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_5175621cf425415c98daaa0026c187c9
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11905035
proquest_miscellaneous_3177152905
pubmed_primary_40084242
crossref_primary_10_1177_17562864251325338
PublicationCentury 2000
PublicationDate 2025-01-01
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – month: 01
  year: 2025
  text: 2025-01-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in neurological disorders
PublicationTitleAlternate Ther Adv Neurol Disord
PublicationYear 2025
Publisher SAGE Publications
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE Publishing
References e_1_3_5_27_2
e_1_3_5_25_2
e_1_3_5_23_2
e_1_3_5_21_2
e_1_3_5_44_2
e_1_3_5_46_2
e_1_3_5_48_2
e_1_3_5_29_2
e_1_3_5_40_2
e_1_3_5_42_2
e_1_3_5_7_2
e_1_3_5_9_2
e_1_3_5_3_2
e_1_3_5_5_2
e_1_3_5_39_2
Wang Y-Q (e_1_3_5_51_2) 2018; 16
e_1_3_5_16_2
e_1_3_5_37_2
e_1_3_5_14_2
e_1_3_5_12_2
e_1_3_5_35_2
e_1_3_5_10_2
e_1_3_5_33_2
e_1_3_5_54_2
e_1_3_5_56_2
e_1_3_5_18_2
e_1_3_5_50_2
e_1_3_5_52_2
e_1_3_5_31_2
e_1_3_5_28_2
e_1_3_5_26_2
e_1_3_5_24_2
e_1_3_5_22_2
e_1_3_5_43_2
e_1_3_5_45_2
e_1_3_5_47_2
e_1_3_5_49_2
e_1_3_5_2_2
e_1_3_5_41_2
e_1_3_5_8_2
e_1_3_5_20_2
e_1_3_5_4_2
e_1_3_5_6_2
e_1_3_5_17_2
e_1_3_5_38_2
e_1_3_5_15_2
e_1_3_5_36_2
e_1_3_5_13_2
e_1_3_5_34_2
e_1_3_5_11_2
e_1_3_5_32_2
e_1_3_5_55_2
e_1_3_5_19_2
e_1_3_5_53_2
e_1_3_5_30_2
References_xml – ident: e_1_3_5_23_2
  doi: 10.1111/j.1528-1167.2011.03041.x
– ident: e_1_3_5_11_2
  doi: 10.1016/j.seizure.2013.05.018
– ident: e_1_3_5_2_2
  doi: 10.1016/S0140-6736(18)32596-0
– ident: e_1_3_5_21_2
  doi: 10.1111/epi.17155
– ident: e_1_3_5_8_2
  doi: 10.1016/j.seizure.2016.11.006
– ident: e_1_3_5_7_2
  doi: 10.1093/brain/awab401
– ident: e_1_3_5_16_2
  doi: 10.1016/j.yebeh.2019.106661
– ident: e_1_3_5_33_2
  doi: 10.1007/s11136-005-4346-x
– ident: e_1_3_5_29_2
  doi: 10.1016/S1474-4422(06)70415-X
– ident: e_1_3_5_25_2
  doi: 10.1016/j.yebeh.2022.108688
– ident: e_1_3_5_6_2
  doi: 10.1111/epi.17564
– ident: e_1_3_5_32_2
  doi: 10.1007/s11136-015-1056-x
– ident: e_1_3_5_20_2
  doi: 10.1111/epi.12550
– ident: e_1_3_5_40_2
  doi: 10.1016/j.neubiorev.2016.05.008
– ident: e_1_3_5_50_2
  doi: 10.1016/j.seizure.2020.04.003
– ident: e_1_3_5_35_2
  doi: 10.1111/j.1528-1167.2009.02397.x
– ident: e_1_3_5_44_2
  doi: 10.1016/j.expneurol.2007.09.026
– ident: e_1_3_5_27_2
  doi: 10.1016/0165-1781(89)90047-4
– ident: e_1_3_5_52_2
  doi: 10.1016/j.comppsych.2016.08.004
– ident: e_1_3_5_48_2
  doi: 10.1016/j.tins.2014.06.005
– ident: e_1_3_5_26_2
  doi: 10.1001/archneur.1989.00520460115022
– ident: e_1_3_5_3_2
  doi: 10.1016/S0140-6736(23)01048-6
– ident: e_1_3_5_41_2
  doi: 10.1146/annurev-med-052209-100430
– ident: e_1_3_5_46_2
  doi: 10.1007/s13311-021-01021-w
– ident: e_1_3_5_10_2
  doi: 10.1016/j.yebeh.2014.02.019
– ident: e_1_3_5_45_2
  doi: 10.1016/j.smrv.2021.101466
– ident: e_1_3_5_13_2
  doi: 10.1111/epi.17664
– ident: e_1_3_5_49_2
  doi: 10.1111/epi.17107
– ident: e_1_3_5_9_2
  doi: 10.1016/j.seizure.2015.12.003
– ident: e_1_3_5_19_2
  doi: 10.1016/j.seizure.2022.10.019
– ident: e_1_3_5_47_2
  doi: 10.1016/j.yebeh.2022.108565
– ident: e_1_3_5_5_2
  doi: 10.1016/S1474-4422(23)00151-5
– ident: e_1_3_5_38_2
  doi: 10.1016/j.seizure.2020.10.029
– ident: e_1_3_5_39_2
  doi: 10.1016/j.yebeh.2023.109568
– ident: e_1_3_5_12_2
  doi: 10.1016/j.smrv.2005.03.002
– ident: e_1_3_5_28_2
  doi: 10.1212/WNL.0000000000200959
– ident: e_1_3_5_55_2
  doi: 10.1212/WNL.0000000000209821
– ident: e_1_3_5_17_2
  doi: 10.1016/j.seizure.2022.11.002
– ident: e_1_3_5_56_2
  doi: 10.1111/epi.17454
– ident: e_1_3_5_22_2
  doi: 10.1111/epi.13709
– ident: e_1_3_5_36_2
  doi: 10.1016/j.yebeh.2017.04.030
– ident: e_1_3_5_42_2
  doi: 10.1111/j.1528-1167.2008.01902.x
– ident: e_1_3_5_53_2
  doi: 10.1016/j.sleep.2018.05.010
– ident: e_1_3_5_4_2
  doi: 10.1001/jama.2022.3880
– volume: 16
  start-page: 5
  year: 2018
  ident: e_1_3_5_51_2
  article-title: The mutual interaction between sleep and epilepsy on the neurobiological basis and therapy
  publication-title: Curr Neuropharmacol
– ident: e_1_3_5_24_2
  doi: 10.1097/WNP.0000000000000806
– ident: e_1_3_5_43_2
  doi: 10.1212/WNL.0b013e3181f25b16
– ident: e_1_3_5_14_2
  doi: 10.1016/j.smrv.2022.101689
– ident: e_1_3_5_31_2
  doi: 10.1111/epi.13651
– ident: e_1_3_5_34_2
  doi: 10.1016/j.yebeh.2015.03.012
– ident: e_1_3_5_30_2
  doi: 10.1111/epi.17710
– ident: e_1_3_5_15_2
  doi: 10.1111/epi.17661
– ident: e_1_3_5_18_2
  doi: 10.1111/epi.13741
– ident: e_1_3_5_54_2
  doi: 10.1038/s41398-022-02297-y
– ident: e_1_3_5_37_2
  doi: 10.1007/s00415-018-8971-z
SSID ssj0062740
Score 2.3460398
Snippet Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy Why was the...
Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have...
Background: Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 17562864251325338
SubjectTerms Original Research
Title Fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy
URI https://www.ncbi.nlm.nih.gov/pubmed/40084242
https://www.proquest.com/docview/3177152905
https://pubmed.ncbi.nlm.nih.gov/PMC11905035
https://doaj.org/article/5175621cf425415c98daaa0026c187c9
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB3SBEovIW3axk27qJBTWVP5Q5Z0bEqWUEgopYG9GXkktwuJ18S7hw358R3J3iXbFnLJwRdb2GJmrHmjGb0BODGZqFNeYCwKZSlAkTbWhcxjm0jjjCoMhkNhF5fF-VX-bSqmD1p9-Zqwnh64F9xnQf6tSBOsybjI2aBW1hjjQwdMlMRwdI983jqY6tdg31BmncP09ErhHYqgtqDgiwCO2vJCgaz_fwjz70LJB55ncgD7A2RkX_qpvoQd17yC5xdDUvwQ7ick3V9LN2bdtXMt689JrsZsU-XasG510y7mN92YmcbS5Vswz-6Wt46F5HpQD6PBHk2SGbBZwwbG1Y75rVpG6Pt6xWxfmOcscy0tJ223eg1Xk7OfX8_joalCjHnKF7HOCZPJTHHkBU815t5Nc9RCYUbSqXmWEWwg1-msUVhZtFWdmMpkXJOyyc-9gd1m3rgjYFjwSlY1rRHax1lcSUcGwdGgoLgRdQSf1kIu2547o0wGevF_NBLBqVfDZqCnvQ43yBjKwRjKx4whgo9rJZb0m_jch2ncfNmVBJMkQRXNRQRve6VuPpX7pgIEVSJQW-remsv2k2b2O1BxJ4SnBM_Eu6eY_TG8SH134bDB8x52F7dL94Egz6IawTM5lSPYOz27_P5jFGz9D43UAW4
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fatigue%2C+sleep+quality%2C+depression+symptoms%2C+and+antiseizure+medication+resistance+in+patients+with+newly+diagnosed+epilepsy&rft.jtitle=Therapeutic+advances+in+neurological+disorders&rft.au=Zhong%2C+Rui&rft.au=Zhao%2C+Teng&rft.au=Li%2C+Nan&rft.au=Li%2C+Jing&rft.date=2025-01-01&rft.issn=1756-2864&rft.eissn=1756-2864&rft.volume=18&rft_id=info:doi/10.1177%2F17562864251325338&rft.externalDBID=n%2Fa&rft.externalDocID=10_1177_17562864251325338
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-2864&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-2864&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-2864&client=summon